$-0.08
(Market cap
$115 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
48,307,896
10 Years Aggregate
CFO
$-241.47 Mln
EBITDA
$-287.47 Mln
Net Profit
$-271.44 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cassava Sciences (SAVA)
| -39.1 | -26.5 | -44.0 | -31.9 | -64.9 | -50.2 | -23.3 |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cassava Sciences (SAVA)
| -16.1 | -89.3 | -23.8 | -32.4 | 540.8 | 31.2 | 511.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cassava Sciences (SAVA)
|
1.2 | 115.0 | 0.8 | -77.9 | -8,786.2 | -104.1 | -- | 0.9 |
| 75.0 | 10,307.9 | 622.0 | -300.9 | -30.1 | -62 | -- | 17.6 | |
| 247.1 | 14,777.7 | 867.5 | 506.6 | -2.8 | -- | 27.2 | 25.9 | |
| 76.9 | 10,379.7 | 105.8 | -829.6 | -715.0 | -- | -- | 60.5 | |
| 50.2 | 12,233.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.1 | 6.5 | |
| 119.0 | 13,020.0 | 1,080.2 | -433.2 | -39.8 | -- | -- | 60.9 | |
| 299.5 | 8,785.0 | 417.3 | 225.0 | 42.8 | 18.6 | 39.9 | 6.8 | |
| 517.3 | 11,800.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.7 | |
| 432.8 | 11,992.5 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.4 | 20.0 | |
| 343.6 | 8,938.2 | 0.0 | -326.5 | -- | -37.2 | -- | 6.3 |
Shareholding Pattern
View DetailsAbout Cassava Sciences (SAVA)
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and... investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas. Address: 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731 Read more
-
Founder, Chairman, President & CEO
Mr. Remi Barbier
-
CEO, President & Director
Mr. Richard Jon Barry
-
Headquarters
Austin, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cassava Sciences (SAVA)
What is the current share price of Cassava Sciences Inc (SAVA) Today?
The share price of Cassava Sciences Inc (SAVA) is $1.21 (NASDAQ) as of 12-May-2026 09:30 EDT. Cassava Sciences Inc (SAVA) has given a return of -64.91% in the last 3 years.
What is the current PB & PE ratio of Cassava Sciences Inc (SAVA)?
Since, TTM earnings of Cassava Sciences Inc (SAVA) is negative, P/E ratio is not available.
The P/B ratio of Cassava Sciences Inc (SAVA) is 0.92 times as on 12-May-2026, a 77 discount to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-4.56
|
0.76
|
|
2023
|
-9.72
|
6.88
|
|
2022
|
-16.30
|
5.19
|
|
2021
|
-53.59
|
6.71
|
What is the 52 Week High and Low of Cassava Sciences Inc (SAVA)?
The 52-week high and low of Cassava Sciences Inc (SAVA) are Rs 4.98 and Rs 1.20 as of 23-May-2026.
What is the market cap of Cassava Sciences Inc (SAVA)?
Cassava Sciences Inc (SAVA) has a market capitalisation of $ 115 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cassava Sciences Inc (SAVA)?
Before investing in Cassava Sciences Inc (SAVA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.